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Abstract
Introduction: Endothelial progenitor cells (EPC) capable of initiating or augmenting vascular growth were recently
identified within the small population of CD34-expressing cells that circulate in human peripheral blood and which
are considered hematopoietic progenitor cells (HPC). Soon thereafter human HPC began to be used in clinical trials
as putative sources of EPC for therapeutic vascular regeneration, especially in myocardial and critical limb
ischemias. However, unlike HPC where hematopoietic efficacy is related quantitatively to CD34+ cell numbers
implanted, there has been no consensus on how to measure EPC or how to assess cellular graft potency for
vascular regeneration. We employed an animal model of spontaneous neovascularization to simultaneously
determine whether human cells incorporate into new vessels and to quantify the effect of different putative
angiogenic cells on vascularization in terms of number of vessels generated. We systematically compared
competence for therapeutic angiogenesis in different sources of human cells with putative angiogenic potential, to
begin to provide some rationale for optimising cell procurement for this therapy.
Methods: Human cells employed were mononuclear cells from normal peripheral blood and HPC-rich cell sources
(umbilical cord blood, mobilized peripheral blood, bone marrow), CD34+ enriched or depleted subsets of these,
and outgrowth cell populations from these. An established sponge implant angiogenesis model was adapted to
determine the effects of different human cells on vascularization of implants in immunodeficient mice.
Angiogenesis was quantified by vessel density and species of origin by immunohistochemistry.
Results: CD34+ cells from mobilized peripheral blood or umbilical cord blood HPC were the only cells to promote
new vessel growth, but did not incorporate into vessels. Only endothelial outgrowth cells (EOC) incorporated into
vessels, but these did not promote vessel growth.
Conclusions: These studies indicate that, since EPC are very rare, any benefit seen in clinical trials of HPC in
therapeutic vascular regeneration is predominantly mediated by indirect proangiogenic effects rather than through
direct incorporation of any rare EPC contained within these sources. It should be possible to produce autologous
EOC for therapeutic use, and evaluate the effect of EPC distinct from, or in synergy with, the proangiogenic effects
of HPC therapies.
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Introduction
Circulating endothelial progenitor cells (EPC) were first
recognized in 1997 [1,2], introducing the concept that cir-
culating EPC might supplement local angiogenesis which
had heretofore been viewed as arising solely by outgrowth
from pre-existing vasculature. Thus EPC had potential for
development of cell-based therapeutic angiogenesis. EPC
in adults were proposed to share a common stem cell with
hematopoietic progenitor cells (HPC)[3], and like HPC
express CD34 and mobilize from bone marrow [1,2]. It
was proposed that, in the absence of a precise phenotype
definition, EPC would coincide with HPC. Consequently,
development of therapy progressed rapidly through precli-
nical studies to early clinical studies by employing HPC
sources as therapeutic cells on the presumption that these
contained EPC. It was shown that such procedures were
safe and showed modest benefit in the treatment of myo-
cardial and peripheral ischemia [4-6].
It was widely supposed that any therapeutic benefit was
mainly achieved by delivery of EPC that home to sites of
active angiogenesis where they proliferate and incorpo-
rate into new vasculature. If this is correct, efficacy
should be related to the quantity of EPC delivered. How-
ever, it was recognised early that therapeutic angiogenesis
is complex [5], and continuing studies of therapeutic
angiogenesis by HPC in cardiac [7,8] and peripheral
[9,10] ischemias have not shown consistent clinical effi-
cacy. This lack of obvious clinical benefit has led to calls
for a better understanding of the identities and roles of
cells participating in angiogenesis where there is recogni-
tion of the distinct effects of direct participation (incor-
poration) and indirect promotion (paracrine effect), so
that the cell-based therapies can be designed to be more
beneficial[11,12]. This might be achieved by sourcing,
enrichment and manipulation of appropriate effector
cells when such cells and their roles can be defined.
Reported clinical studies have all employed autologous
bone marrow or mobilized peripheral blood HPC as the
therapeutic source, either as unfractionated mononuclear
cells (MNC) or as enriched HPC by selection of CD34+
or CD133+ MNC. However since the identity of EPC has
been ambiguous, there can be no confidence that the
most appropriate therapeutic cells have been employed.
For example, the issue as to whether or not EPC express
CD133 has been controversial, but is now resolving to
indicate that EPC do not express CD133 [13-15], so it
seems that some trials that have employed CD133-
enriched HPC may not have delivered EPC in the
implanted cells. Although a variety of sources and cell
fractions have been employed for therapeutic angiogen-
esis in both myocardial and peripheral ischemia, these
cells have not been systematically compared in clinical
trials. In such studies there is also no apt means to
discriminate the direct and indirect contribution of
engrafted cells and it has generally been presumed, rather
than established, that any vascular regeneration may be
attributed to engrafted EPC.
Our aim in this study was to provide some basis to
inform decisions on sourcing and possible in vitro
manipulation of cells for vascular regeneration therapy.
Unlike the use of HPC in hematopoietic reconstitution,
where there is consensus that therapeutic efficacy can
be related to the number of CD34+ cells administered
[16-18], there are no established in vitro tests to assess
the relative angiogenic potency of a particular cell popu-
lation. Very recent studies may have resolved issues over
the phenotype of EPC that may allow their quantitation,
but have yet to be widely accepted and applied [14]. In
any case, vascular regeneration is likely to be complex
and not simply dependent quantitatively on EPC avail-
ability, since there may be indirect paracrine potentia-
tion of intrinsic angiogenic capacity by implanted cells
as well as direct participation by incorporation of
engrafted EPC [19-22,12]. We therefore adapted an
established animal model of angiogenesis [23] to exam-
ine the effects of embedded test cells on the sponta-
neous vascularization of subcutaneously implanted
sponge pellets in mice. Besides quantitative effects (ves-
sel density in recovered sponges) this also allows vessel
origin (mouse host or human implant) to be discrimi-
nated by species. Our aim in this investigation was to
systematically evaluate and compare the effects in this
model on vessel density and vessel origin of various
potential clinical sources of EPC. A range of human
sources of putative EPC and other cells of interest was
embedded in sponge pellets prior to implantation, and
recovered sponges were assessed both for changes in
vessel density and for any incorporation of implanted
human cells into vessel walls. In this study we have
examined the prima facie differences between cells from
different sources or enrichment/depletion from the
same source, as they might be used clinically, in order
to characterise these. We have not in this initial study
attempted to investigate the underlying mechanisms
behind the observed differences, which will be examined
in subsequent studies, but we speculate on these by
reference to the published work.
Materials and methods
Human cells
We prospectively examined the following potential
sources of human EPC: 1) CD34+ enriched and depleted
MNC from different HPC sources; 2) putative proangio-
genic monocytes; and 3) endothelial outgrowth cells
(EOC) and mature human umbilical vein endothelial
cells (HUVEC).
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Samples were obtained, with appropriate informed con-
sent under ethical approval granted by South East Scot-
land Research Ethics Committee 2 (reference 09/S1102/
35), of human bone marrow aspirates, venous peripheral
blood and umbilical cord blood, as previously described
[24,25]. Mononuclear cells (MNC) were isolated by buoy-
ant density centrifugation, HPC (CD34+) were enriched to
> 95% purity using magnetic beads (MACS CD34 Isolation
Kit, Miltenyi Biotec, UK) employing two passes on reten-
tion columns, and plastic (2-h) and fibronectin (48-h)
adherent cells were enriched/depleted, all as previously
described [24,25], where fibronectin adherence was carried
out on fibronectin-coated vessels (BD BioCoat Cellware,
Becton-Dickinson, UK) in EndoCult Medium (Stemcell
Technologies SARL, Grenoble, France), and plastic adher-
ence was carried out in polystyrene tissue culture flasks
(Corning) in IMDM (Life Technologies, Scotland). In our
hands 2-h plastic-adherent MNC or 48-h fibronectin non-
adherent MNC both contain all the cells that give rise to
CFU-Hill colonies, formerly called colony-forming units
endothelial progenitor cells (CFU-EPC), after 4 to 6 further
days culture on fibronectin in EndoCult Medium [24,25].
These are the so-called early EPC colonies now known to
derive from monocytes [26-28]. As reported by others
[29], we have found that these early CFU-EPC do not arise
by proliferation: our time-lapse studies show that they
arise by migration to aggregates, which subsequently dis-
perse (unpublished). We cannot therefore enrich these
cells by outgrowth culture and instead we selected MNC
populations in which they reside. EOC and other out-
growth cells were obtained by outgrowth from MNC pla-
ted on type-1 collagen-coated polystyrene vessels (BD
BioCoat Cellware, Becton-Dickinson, UK) in endothelial
growth medium (EGM-2, Lonza) as previously described
[25], after the method of Ingram et al. [30]. EOC colonies
first appear at between 2 to 3 weeks in culture with fre-
quent medium changes which remove non-adherent cells.
EOC were derived from cord blood MNC, normal periph-
eral blood MNC and fetal liver MNC, but never from G-
CSF-mobilized peripheral blood MNC [25]. Outgrowth
cells obtained from bone marrow MNC by this method
were consistently mesenchymal stromal cells (MSC), as
reported by others [31]. These bone marrow derived MSC
differentiated to bone or adipose tissue but failed to form
tubules in Matrigel (Tura et al., manuscript submitted).
HUVEC were purchased (cryopreserved Clonetics single
donor cells, Lonza) and cultured in EGM-2 on uncoated
tissue culture vessels (Corning). Unless otherwise stated,
outgrowth cells and HUVEC were used after the second
or third passage of expansion culture in EGM-2, where
cells were passaged after reaching approximately 90% con-
fluence. Where HUVEC isolates (not passaged) were used
these were thawed on delivery and allowed to recover in
culture for two days in EGM-2 before implantation.
Sponge implant model
Male immunodeficient NSG mice aged 10 to 12 weeks
were used in procedures approved by the University of
Edinburgh ethics committee and authorized by the UK
Home Office. Anesthetic comprised Vetalar (7.5 mg/ml)
and Dormitor (100 μg/ml) in water for injection, given
intraperitoneally at a dose of 0.065 μl/10 gbw. Reversal of
anesthesia was induced, after at least 20 minutes of
unconsciousness, using Antisedan (200 μg/ml) in water
for injection. This was given subcutaneously at a dose of
0.05 ml/10 gbw. Mice were anesthetized and a sterilized
polyurethane sponge cylinder (0.5 cm × 1 cm) (Caligen
Foam, Accrington, Lancashire, UK) was implanted sub-
cutaneously on each flank. Phenol-red free growth fac-
tor-reduced (gfr)-Matrigel® (BD Biosciences) was used as
vehicle to retain 1 × 105 test cells in sponges before
implantation. Cells were spun down in tubes and resus-
pended in 100 μL ice-cold gfr-Matrigel, and a dry sterile
sponge pellet was tamped into this in a tube to absorb
the cell suspension (contralateral implant control
sponges were loaded with gfr-Matrigel without cells). On
coming to room temperature the Matrigel gelled, retain-
ing the cells within sponges prior to implantation. We
used gfr-Matrigel instead of normal Matrigel since gfr-
Matrigel contains fewer growth factors, which might
mask any cell-derived effects. There was no difference in
spontaneous vascularization between untreated sponges
(without gfr-Matrigel) and sponges with gfr-Matrigel
(both without cells) in direct comparisons (paired in the
same mice) in preliminary experiments. Replicate (groups
of 4) mice were implanted simultaneously with each test
cell isolate from any given donor. Each animal had a test
sponge (gfr-Matrigel + cells) on one side and a control
sponge (gfr-Matrigel alone) on the other side, as pre-
viously described [25]. Twenty-one days after implanta-
tion, mice were killed by asphyxiation in CO2 and
sponges were excised. Sponges were fixed in 4% formalin
and were embedded in paraffin wax for subsequent
microtome sectioning for histological staining to quantify
vessel density [23] and for immunohistochemical analysis
to evaluate species origin.
Histology and immunohistochemistry
Sponge sections (8 μm) were cut from paraffin blocks by
microtome, mounted on glass slides, de-waxed, rehydrated
and stained with hematoxylin/eosin for identification of
blood vessels, characterised by a nucleated lumen sur-
rounding non-nucleated eosin-stained red cells, as pre-
viously described [23]. Vessel density was determined by
Chalkley counts as previously described [23], at three loca-
tions on each of two sections, with a microscope with a
25-point Chalkley eyepiece graticule and a ×40 objective.
Immunohistochemistry was developed for this study.
Antibodies were pre-assessed for endothelial specificity
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and species cross-reactivity on sections from formalin-
fixed and paraffin-embedded mouse and human vascular
tissue, and on various cultured endothelial cells, using
the same staining methods as used for experimental
sponge sections. Sponge sections were stained with sets
of paired anti-endothelial antibodies where rabbit cross-
reactive (to mouse and human) antibody was paired
with mouse human-specific antibody. Binding of rabbit
and mouse antibodies was determined by subsequent
staining with species-specific fluorochrome-conjugated
secondary antibodies, namely goat anti-rabbit IgG Alexa
488 conjugate (green fluorescence) together with goat
anti-mouse IgG Alexa 555 conjugate (red fluorescence).
Diamidino-2-phenylindole (DAPI) staining (blue fluores-
cence) identified cell nuclei. The primary antibody com-
binations used were as follows: Set 1 (control): no
primary antibodies (diluent only during first staining
stage); Set 2: rabbit anti-a-smooth muscle actin (SMA)
(Epitomics 1184-1) paired with mouse anti-CD31 (Dako
M0823); Set 3: rabbit anti-CD31 (Epitomics 2540-1)
paired with mouse anti-CD146 (AbCam ab49492); Set 4:
rabbit anti-CD105 (endoglin) (Aviva ARP33069) paired
with mouse anti-CD106 (VCAM-1) (Santa Cruz sc-
13160); Set 5: rabbit anti-CD146 (Epitomics 2505-1)
paired with mouse anti-vWf (von Willebrand Factor)
(Monosan MONX10598).
Sections on microscope slides were de-waxed and rehy-
drated as for histological hematoxylin staining, then sub-
jected to epitope recovery by simmering in EDTA solution
pH 8.0 (Life Technologies) for 20 minutes in a microwave,
then cooled and washed. These were blocked (Image-iT-
FX signal enhancer, Life Technologies), then stained over-
night at 4°C with one of a selection of cross-reactive rabbit
anti-endothelial (monoclonal and polyclonal) antibodies
mixed with one of a selection of human-specific mouse
monoclonal antibodies, paired as above. Staining was in a
diluent comprised of Dulbecco’s phosphate buffered saline
pH 7.2 containing 0.5% Tween 20, 0.01% sodium azide
and 2% goat serum and washes used the above diluent
without goat serum. Primary and secondary antibodies
were used generally at 1/200 in the diluent, and staining
was carried out on duplicate sections mounted on each
slide, using 150 μL of diluted antibodies on slides
mounted, blocked and pre-washed in a staining rack
(Shandon Sequenza). Sets of sections from one or more
sponges were stained simultaneously with the panel of dif-
ferent primary antibodies above. After multiple washes,
binding of rabbit and mouse antibodies was determined by
subsequent staining for 3 h at 37°C with a mixture of
secondary antibodies goat anti-mouse IgG Alexa 555 con-
jugate (red fluorescence) (Life Technologies A21424) and
goat anti-rabbit IgG Alexa 488 conjugate (green fluores-
cence) (Life Technologies A11034), followed by washing
then mounting under coverslips in anti-fade mountant
(ProLong Gold, Life Technologies) containing DAPI (blue
fluorescence) to identify cell nuclei. Stained and mounted
slides were stored at 4°C in the dark.
For each primary antibody pair two sections from each
sponge were stained, and were examined using a Zeiss
Axio-Observer A1 microscope equipped with appropriate
filter combinations, and illustrative images were recorded
using a high sensitivity Zeiss AxioCam MRm (black &
white) camera. For each field images were captured under
normal tungsten (phase-contrast) illumination and under
UV illumination for each of blue, green and red channels
with appropriate filters for each fluorochrome. Automated
exposure for image capture (determined by Zeiss AxioVi-
sion software V 4.8) was optimized on the brightest object
in a given field (max/min exposure). Images were cap-
tured, colored according to channel, and processed for sin-
gle and combined channel images using Zeiss AxioVision
(v 4.8) software. Detection of green fluorescence was taken
as indicating binding of the primary rabbit cross-reactive
antibody, and detection of red fluorescence was taken as
indicating binding of the primary mouse human-specific
antibody. Presence of green without red indicated mouse
(host) tissue while both green and red together indicated
human (cell implant) tissue: nucleated cells stained with
DAPI (blue). Erythrocytes within perfused vessels were
autofluorescent in both the red and green channels and
lacked nuclei by DAPI stain. In the absence of specific
immunofluorescence, erythrocyte autofluorescence domi-
nated captured images due to longer automated expo-
sures, but could appear minimal in any channel that
showed bright specific immunofluorescence, which was
maximal at shorter exposures. In the presence of immuno-
fluorescence in only one (green or red) channel, the ery-
throcyte autofluorescence image was diminished in that
channel but retained in the other, so that mouse-only ves-
sels showed green immunofluorescent walls (from cross-
reactive rabbit anti-endothelial antibody) surrounding red
autofluorescent erythrocytes. Primary interpretation was
based on extensive visual examination using a ×40 objec-
tive of the whole sponge section, and on comparison to
control unstained sections (without primary antibodies)
and to host (mouse-only) vessels in sections from sponta-
neously vascularized contralateral-control sponges without
implanted human cells. Identification of integration of
human cells into vessels was based on visual scanning for
red fluorescence resulting from bound human-specific
antibody. Representative images of selected fields were
recorded for illustration, and after processing provided
composite multicolor images showing co-localisation of
specific immunostaining and relative location of autofluor-
escence. Patterns of specific immunofluorescence and the
relative brightness of erythrocyte autofluorescence in
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images also informed interpretation of whether or not
implanted human derived cells were incorporated into the
sponge vessels.
Statistical methods
Results are reported for equivalent cell fractions from dif-
ferent donors (different mouse group replicates) which
were pooled and analyzed by repeat-sample analysis of
variance (ANOVA) as in our previously described use of
the sponge implant model [23], using NCSS 2007 software
(Statistical Solutions).
Results
Implantation of CD34+-enriched or -depleted
mononuclear cells
MNC from G-CSF-mobilized peripheral blood, umbilical
cord blood and bone marrow and their CD34-enriched
and -depleted fractions were assessed in a series of experi-
ments (Table 1). Unfractionated MNC from any source
had no apparent effect on vessels (not shown). CD34-
enriched MNC from G-CSF-mobilized peripheral blood
(Figure 1A) or umbilical cord blood (Figure 1B) signifi-
cantly increased vessel density, whereas the corresponding
CD34-depleted MNC from any source had no effect on
vessel density (Figure 1). CD34-enriched MNC from bone
marrow had no effect on vessel density (Figure 1C).
Immunohistochemical analysis showing representative
examples of vessels comprised exclusively of mouse cells is
shown in Figure 2 where (b) CD34-enriched cord blood
MNC or (c) CD34-depleted cord blood MNC were
implanted in sponges. Further examples of vessel immu-
nohistochemistry images using sponges with a range of
implanted cells and stained with the different primary
antibody combinations are shown in Additional file 1.
None of these implanted MNC from any source, or
whether the MNC were CD34-enriched or depleted,
incorporated into vessels (Table 1).
Implantation of putative proangiogenic monocytes
Neither plastic-adherent MNC, their residual non-adher-
ent counterparts, nor MNC not adherent to fibronectin
after 48-h culture had any effect on endogenous vessel
density, nor did they incorporate into vessels (Table 2).
All vessels stained with the cross-reactive rabbit anti-
endothelial cell antibodies but none stained with human-
specific mouse anti-endothelial antibodies, indicating
these vessels were comprised exclusively of endogenous
mouse cells. However, when plastic-adherent MNC (>
80% monocytes) were implanted, some microscopy fields
contained dispersed cells (not in vessels) of human origin
since they stained with the human-specific antibodies as
well as the cross-reactive antibodies (Figure 2d). These
dispersed cells were also detected less prominently in
other experiments when MNC containing monocytes
were implanted. It was noted that these isolated cells
were also detected by anti-CD105 (endoglin) paired with
anti-CD106 (see Additional file 1, Figure 4b). The anti-
CD106 does not detect human endothelial cells which
have integrated into vessels (see below). These cells were
interpreted as human monocytes that have upregulated
expression of endothelial markers (CD31, CD105,
CD106, CD146) during the 3 weeks of implantation.
They were not apparently detected (none were seen) by
anti-a-SMA or anti-vWf antibodies.
Table 1 Implantation of CD34+-enriched mononuclear cells from mobilized blood or cord blood enhances
vascularization in subcutaneous sponge implants without incorporation into vessels
Vessel density (Chalkley counts)
Source Implanted cells Untreated Treated Difference Probability level
(ANOVA)
Incorporation into
vessels
Mobilized peripheral blood
(donors: n = 2)
CD34-enriched MNC
(mice: n = 8)
3.833 (0.661) 10.250 (1.254) 6.417 (0.785) 0.00008* No
CD34-depleted MNC
(mice: n = 8)
5.021 (1.023) 5.208 (0.465) 0.187 (0.710) 0.799 No
Umbilical cord blood
(donors: n = 2)
CD34-enriched MNC
(mice: n = 7)
3.929 (0.655) 7.405 (0.957) 3.476 (1.207) 0.028* No
CD34-depleted MNC
(mice: n = 8)
3.604 (1.200) 4.437 (0.836) 0.833 (1.568) 0.603 No
Bone marrow
(donors: n = 3)
CD34-enriched MNC
(mice: n = 10)
6.483 (0.509) 7.433 (1.047) 0.950 (1.003) 0.368 No
CD34-depleted MNC
(mice: n = 10)
6.317 (0.752) -0.167 (1.226) 0.895 No
Implantation of CD34+-enriched mononuclear cells (MNC) from granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood or umbilical cord blood
significantly increased new vessel formation in subcutaneous sponges (*P < 0.05). Vessel density was increased between paired cell-impregnated sponges
compared to contralateral control sponges without cells. Implantation of CD34+-enriched MNC from bone marrow and CD34+-depleted MNC from any source
had no significant effect on vessel density. No human cells incorporated into vessels. Data are means, with standard errors in parentheses. Probability was
determined by repeat-sample analysis of variance (ANOVA) on individual readings for each mouse from pooled data from different donors.
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CD34+-enriched MNC CD34+-depleted MNC
(A) G-CSF-mobilised peripheral blood
(B) umbilical cord blood
(C) bone marrow
Figure 1 CD34+-enriched mononuclear cells increase angiogenesis in sponges. Impregnation of sponges with CD34+-enriched MNC
(mononuclear cells) from (A) granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood or (B) umbilical cord blood, significantly
increased vascular density within sponges compared to contralateral sponges without cells. CD34+-enriched MNC from bone marrow (C) and
CD34+-depleted cells from any source had no effect. The replicate means of paired Chalkley counts are shown for all mice receiving each kind
of cell fraction from each source. The data are pooled from different experiments where different donors contributed to sets of enriched and
depleted cells. Data were analyzed comparing individual count results for sponge pairs from each mouse (n = number of mice) for each cell
type and source by repeat-measure analysis of variance.
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Figure 2 Representative examples of vessels detected in sponge sections. The images show (a) unstained control; (b, c) mouse-only
vessels; (d) free human cells not in vessels; and (e, f) vessels with human cells in vessel walls. Cells implanted: (a) endothelial outgrowth cells
(EOC); (b) CD34+-enriched cord blood MNC; (c) CD34+-depleted cord blood MNC; (d) plastic-adherent MNC (> 80% monocytes); (e) EOC; (f)
EOC. Column 1 is the phase-contrast image; column 2 is the image from the green fluorescence channel merged with blue fluorescence
showing diamidino-2-phenylindole (DAPI) nuclear stain; column 3 is red fluorescence merged with the blue DAPI nuclear stain; and column 4 is
the merged image from green, red and blue fluorescence. The antibody pairs shown are (b, e) cross-reactive (rabbit) anti-a-smooth muscle actin
with human-specific (mouse) anti-CD31 and (c, d, f) cross-reactive (rabbit) anti-CD31 with human-specific (mouse) anti-CD146. Human cells are
identified by red fluorescence revealing bound human-specific antibody (d, e, f), which generally co-localizes with the green fluorescence of
bound cross-reactive antibody. Where only cross-reactive antibodies bind (b, c), the vessel walls show green fluorescence only, indicating mouse
tissue only. In one example (e) some mouse-only (green without red) vessels can be seen together with human vessels (green and red). Where
no antibodies bind, as in the control (a), both red and green erythrocyte autofluorescence is evident in the images, but only the red erythrocyte
autofluorescence is evident (b, c) when vessel walls show green immunofluorescence, and little or no erythrocyte autofluorescence is evident
when vessel walls show both red and green fluorescence. A more comprehensive set of images is given in Additional file 1.
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Implantation of endothelial and other outgrowth cells
EOC were cultured, as previously described [25], from
umbilical cord blood and normal peripheral blood, and
were also obtained from fetal liver MNC. EOC could not
be obtained from G-CSF-mobilized peripheral blood by
this (or any other) method, as previously reported [25], so
were not available for implantation. EOC from all sources
were incorporated into the newly formed vessels in
sponges (Table 3). In these vessels, immunoreactivity was
detected as homogeneous luminal binding of human-spe-
cific mouse anti-CD31 (Figure 2e) and anti-CD146 (Figure
2f) which appeared to co-locate with cross-reactive anti-a-
Table 2 Implantation of putative proangiogenic monocytes does not stimulate vascularization in subcutaneous
sponge implants
Vessel density (Chalkley counts)
Source Implanted cells Untreated Treated Difference Probability level
(ANOVA)
Incorporation into
vessels
normal peripheral blood
(donors: n = 3)
Adherent (plastic) MNC
(mice: n = 11)
5.288 (0.742) 5.106 (0.590) -0.182 (0.796) 0.475 No
Non-adherent (plastic)
MNC
(mice: n = 12)
5.806 (0.844) 5.514 (0.840) -0292 (1.116) 0.799 No
mobilized peripheral
blood
(donors: n = 1)
Adherent (plastic) MNC
(mice: n = 4)
4.833 (0.791) 6.083 (0.647) 1.25 (0.610) 0.133 No
Non-adherent (plastic)
MNC
(mice: n = 4)
6.208 (2.197) 7.583 (1.674) 1.375 (3.152) 0.692 No
normal peripheral blood
(donors: n = 1)
Non-adherent
(fibronectin) MNC
(mice: n = 4)
2.667 (0.853) 4.333 (1.080) 1.667 (1.393) 0.318 No
Implantation of putative proangiogenic monocytes selected on the basis of mononuclear cells (MCN), which contain the cells responsible for early colony-forming
units endothelial progenitor cells (CFU-EPC) by rapid (2h) adherence to plastic or non-adherence to fibronectin after 48 h [24,25], did not significantly increase
new vessel formation in subcutaneous sponges (P > 0.05 for all). Vessel density was not different comparing paired cell-impregnated sponges to contralateral
control sponges without cells. No human cells incorporated into vessels. Data are means, with standard errors in parentheses. Probability was determined by
repeat-sample analysis of variance (ANOVA) on individual readings for each mouse from pooled data from different donors.
Table 3 Implantation of EOC, HUVEC or MSC does not enhance vascularization, but EOC incorporate into vessels
Vessel density (Chalkley counts)
Source Implanted cells Untreated Treated Difference Probability level
(ANOVA)
Incorporation
into vessels
Umbilical cord blood or normal
peripheral blood
(donors: n = 5)
Endothelial outgrowth
cells
(mice: n = 20)
7.528 (0.581) 9.403 (0.671) 1.875 (0.967) 0.078 Yes
Umbilical vein wall
(donors: n = 2)
Human umbilical vein
endothelial cells
(mice: n = 7)
8.238 (1.553) 8.833 (1.492) 0.595 (1.502) 0.706 No
Outgrowth from foetal liver MNC
(donors: n = 1)
Endothelial outgrowth
cells)
(mice: n = 4)
9.25 (1.975) 9.25 (0.308) 0.00 (2.174) 1.000 Yes
Outgrowth from bone marrow
MNC
(donors: n = 1)
Mesenchymal stromal
cells (MSC)
(mice: n = 4)
5.958 (0.893) 8.583 (1.788) 2.625 (2.260) 0.329 No
Umbilical cord blood
(donors: n = 1)
EOC - extended
culture
(11th passage)
(mice: n = 2)
3.667 (2.000) 9.333 (2.500) 5.667 (0.500) 0.056 No
Umbilical vein wall
(donors: n = 1)
HUVEC - early culture
(pre first passage)
(mice: n = 4)
3.958 (1.214) 5.167 (0.649) 1.208 (1.102) 0.353 Yes
Implantation of endothelial outgrowth cells (EOC), human umbilical vein endothelial cells (HUVEC) or mesechymal stromal cells (MSC) did not significantly
increase new vessel formation in subcutaneous sponges (P > 0.05), as measured by the difference in vessel density between paired treated sponges containing
implanted cells and contralateral control sponges without cells. Vessel density was not different comparing paired cell-impregnated sponges to contralateral
control sponges without cells. EOC clearly incorporated into newly formed vessels in all sponges examined, whereas neither HUVEC nor MSC incorporated.
Exceptions were late-passage EOC which did not incorporate, or very early HUVEC which did incorporate. Data are means, with standard errors in parentheses.
Probability was determined by repeat-sample analysis of variance (ANOVA) on individual readings for each mouse from pooled data from different donors.
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SMA and cross-reactive anti-CD31 binding, respectively,
and also punctate luminal binding of anti-vWf co-located
with homogeneous cross-reactive anti-CD146 binding (see
also Additional file 1, Figures 2b, 3b and 5b), demonstrat-
ing the presence of human endothelial cells. Human
CD106 was not detected on vessels in sponges in which
human vessel markers were detected extensively by other
antibodies, but human CD106 was detected in other
sponges on isolated monocyte-derived human cells not in
vessels (see above). From this we infer that CD106 is not
expressed on human endothelial cells that have integrated
into the neo-vessels. Since we could not specifically detect
the vessels containing human cells with anti-CD106, we
could not assess their co-labeling with the paired cross-
reactive anti-CD105 (endoglin), which diffusely labeled
vessels both in the lumen (Additional file 1, Figure 4a) and
apparently in some cases, also in perivascular cells (Addi-
tional file 1, Figure 4a, row C). Where vessels containing
incorporated human cells were identified in sponge sec-
tions, they tended to occur in localized areas and not
throughout the sponge section, where in general the
majority of vessels were of host origin and contained only
mouse endothelial cells. All vessels contained mouse ery-
throcytes indicating that they were perfused and contigu-
ous with the host circulation. Unlike mobilized blood and
cord blood CD34+ MNC (Table 1), these cells did not
enhance endogenous vascularization in the sponges
despite their incorporation, since there was no increase in
vessel density compared to control paired contralateral
sponges without implanted cells.
Under EOC culture conditions, MNC from bone mar-
row consistently produced mesenchymal stromal cells
(MSC), not EOC, as has been reported by others [31].
These MSC had a distinct phenotype from EOC, and
unlike EOC could differentiate to osteoblasts or adipo-
cytes but could not produce endothelial tubules in Matri-
gel® (Tura et al., manuscript submitted). These MSC did
not enhance vascularization in sponges or incorporate
into vessels (Table 3). Effectively, of all the human cells
tested (Tables 1, 2 and 3) only EOC show consistent
incorporation into vessels. In contrast to EOC, HUVEC
showed no incorporation into vessels when EOC or
HUVEC were obtained by our routine culture of two to
three passages from first confluent outgrowth. However,
EOC were unexpectedly found to lose the ability to
incorporate into vessels after extensive culture, in this
case 11 passages (Table 3). In response to this result, and
by way of contrast, an early HUVEC isolate (not grown
to confluence or passaged) was examined, and was found
to still express the ability to incorporate into vessels
(Table 3 and Additional file 1, Figure 3b, row B). HUVEC
did not enhance vascularization in sponges (Table 3).
In our hands, in direct comparisons, cord blood MNC
produced EOC only on culture vessels coated with type-
1 collagen (or sporadically on gelatin, which contains
type-1 collagen), and the same MNC did not produce
EOC when cultured on type-IV collagen, fibronectin or
uncoated tissue culture polystyrene. This was confirmed
in three different cord blood donors.
Discussion
These results reveal that angiogenic potency is not sim-
ply dependent proportionally on EPC numbers, as pro-
posed in many prevailing interpretations, but is complex
and may involve multiple cell types with different roles,
as has been reviewed [11,12]. In our model the angio-
genic potency appears to comprise two distinct activities
mediated by different cells, 1) true endothelial progeni-
tor activity with cell incorporation into vessel walls pro-
vided by EOC, and 2) proangiogenic amplification of
vascularization provided by CD34+ HPC from mobilized
peripheral blood and cord blood, but not from bone
marrow. Different sources of HPC that may have essen-
tially similar clinical hematopoietic potency can have
quite different angiogenic properties, and HPC content
does not predict angiogenic potential. Other cells, such
as monocytes or mesenchymal stromal cells, seem irrele-
vant in this model.
This distinction was not apparent when we proposed
this study in 2006 in anticipation of a need to supply cells
for therapeutic vascular repair in myocardial infarction or
severe peripheral ischemia, which was and still is
focussed primarily on the use of autologous HPC from
bone marrow or mobilized blood, with or without enrich-
ment of HPC by selection of CD34+ or CD133+ cells.
During our studies a number of reports have appeared,
which show 1) that HPC have a proangiogenic effect, par-
ticularly CD133+ HPC [19]; 2) that EOC probably repre-
sent true endothelial progenitors that incorporate into
neo-vessels and are derived from CD34+CD133- cells and
not CD34+CD133+ cells [13,15]; 3) that early CFU-EPC
are derived from monocytes and while these may express
some endothelial markers, they are unrelated to EPC, do
not proliferate, and do not incorporate into vessels
[26-28]; and 4) that mesenchymal stromal cells do not
contribute directly to angiogenesis but may support it
[32]. It is possible to review these individual reports and
come to essentially the same conclusion that we do from
our study, so our conclusions are not original. However,
papers contradicting these findings continue to be pub-
lished, so it is important to provide support for these
conclusions. Also, instead of focussing on a particular
cell, our work systematically compares under the same
conditions, a number of different proposed sources and
subpopulations of cells for therapeutic vascular repair
and shows that they are not equivalent. We provide
important support for the various individual studies
above, for which there is not yet a consensus to judge
Barclay et al. Stem Cell Research & Therapy 2012, 3:23
http://stemcellres.com/content/3/4/23
Page 9 of 15
from the range of interpretation and opinion in many
current publications, and may help provide support for
informed redesign of cellular therapy for vascular repair.
The sponge model, in which the implanted sponge is
spontaneously encapsulated and vascularized by the host,
is often called an inflammatory angiogenesis model [33].
It is an established, widely used model which allows
investigation of angiogenesis in vivo and which was well
suited for the comparison of the effects of different
implanted cells on new vessel formation [23,34]. It is
unlikely that the model replicates exactly the process of
reparative angiogenesis in ischemic tissue [34], and these
results may not necessarily be extrapolated to pathophy-
siological angiogenesis (for example, in response to myo-
cardial infarction or in limb ischemia). In our hands the
sponge model adapted well for the comparison of the
effects of different implanted cells on the angiogenesis
that occurs within these sponges, where it discriminates
between the direct incorporation of implanted cells into
neo-vessels and the proangiogenic stimulation of vessel
number by different implanted cells. However, it may be
that more subtle effects could be masked by the inflam-
matory response to the sponges [33].
In our experience, EOC derive only from a subset of
CD34+/CD133- MNC[25], confirming previous reports
[13,15]. This is contrary to a number of publications stat-
ing that CD133 is found on EPC. This inconsistency in
definition confounds an objective assessment of many
published reports of relationships between EPC and
angiogenic potential that employ different phenotype
bases to quantify or enrich EOC, as reviewed recently
[14]. The subset of CD34+/CD133- cells recently
described by Estes et al. [35] as defining the true EPC
phenotype are extremely rare in circulation and also rare
in accessible sources of HPC such as umbilical cord
blood or mobilized peripheral blood. We find a similar
very rare (fewer than one in a million) MNC subpopula-
tion giving rise to EPC that are CD34+/CD133-/CD45-/
CD146+. If CD146 is an alternative to CD31 for discrimi-
nating EPC then these cells may be the same CD34
+/CD133-/CD45-/CD31+ subpopulation described by
Estes et al. [35] as EPC with in vivo vessel-forming capa-
city. These CD34+/CD133-/CD45-/CD146+ cells can be
detected in normal peripheral blood and cord blood
MNC, both of which give rise to EOC, but are below our
limit of detection in bone marrow or mobilized blood
MNC, neither of which give rise to EOC (Tura et al.,
manuscript submitted). Thus, detection of this cell sub-
population appears to coincide with our ability to grow
EOC from these different sources. We find from out-
growth studies that the frequency of EOC colonies
(endothelial colony-forming cells, ECFC) in cord blood
MNC is approximately one in five million, and is
approximately one in thirty million in normal peripheral
blood MNC. ECFC frequency remains low even in
CD34-enriched MNC, indicating that EPC are a very
small component of total CD34+ cells, but no ECFC are
found in CD34-depleted MNC [25]. Therefore, apart
from homogeneous EOC from culture, the cell popula-
tions implanted in this study will contain very few or no
true EPC as indicated by the very low ECFC frequency,
even when CD34+-enriched cord blood cells are used
[25]. It is not surprising, therefore, that no human cell
incorporation into sponge vessels was found in these
cases.
It may be that adult EPC have been ascribed a close
relationship to HPC by their coincidental expression of
CD34, which is a marker of both hematopoietic progeni-
tors and mature endothelial cells. However, HPC and
EPC might not be as closely related in adults as inferred,
and circulating EPC might not derive from bone marrow.
The endothelial stem cell niche could be principally
located elsewhere, such as in the vasculature itself.
Ingram et al. [36] have described a hierarchy of endothe-
lial lineage cells, including progenitors that can be recov-
ered from vessel walls. This may be why we consistently
fail to recover EOC from G-CSF mobilized blood MNC,
where HPC leave the bone marrow and appear in the cir-
culation but are not apparently accompanied by EPC,
which give rise to EOC [25]. Furthermore, existing circu-
lating EPC could be diluted to below detection by the
leukocytosis which accompanies G-CSF mobilization.
This could also explain why we and others [31] were
unable to grow EOC from bone marrow MNC and
instead obtain mesenchymal stromal cell outgrowth
under conditions that generate EOC when other cell
sources are used. These bone marrow-derived MSC had
no effect in our sponge vascularization model, showing
neither incorporation into vessels, nor promotion of vas-
cularization. Similarly, purchased MSC derived from
human adipose tissue had no effect on sponge vasculari-
zation (not shown).
Melero-Martin et al. [32] have shown that implanted
MSC can contribute to vascularization in implanted
Matrigel plugs by synergizing with implanted human
EOC in co-transplants. Here it was proposed that the
MSC may contribute by secretion of vascular endothelial
growth factor (VEGF) to induce implanted human EOC
to form vessels, and the MSC may also stabilize vessels
by forming perivascular structure around the endothelial-
derived lumen. However, they found that EOC implanted
alone did not result in vascularization of the Matrigel
plug and neither is it spontaneously vascularized by the
host. In contrast in our sponge implant model sponges
are spontaneously vascularized by the host, and MSC
implant did not apparently affect this spontaneous vascu-
larization whereas mobilized or cord blood CD34+ cells
significantly promoted it. From this we can infer that
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these CD34+ cells are more potent than MSC in promot-
ing angiogenesis. We did not study co-implantation of
different cell types, but human EOC implanted alone
without accompanying MSC incorporated into growing
vessels while MSC alone did not, and neither EOC nor
MSC promoted increased vessel density. It seems that
the sponge model and the Matrigel plug model differ.
The sponge model has been used extensively as a model
of angiogenesis and to measure effects of exogenous fac-
tors on this angiogenesis [37,23,34,25]. It may be that
since no spontaneous host vascularization takes place in
the Matrigel plug, that model may reflect de novo vascu-
logenesis. It may also be that vasculogenesis and angio-
genesis depend differently on EPC and accessory cells,
accounting for the differences between our findings and
those reported by Melero-Martin et al. [32]. Since the
sponge model indicates that available EOC are incorpo-
rated when new vessels form, it may be that the Matrigel
plug model says more about the ability of the cells that
are co-transplanted with EOC to promote vessel forma-
tion than about the inherent capacity of EOC to form
vessels.
Melero-Martin et al. [32] also used anti-a-SMA anti-
body to discriminate MSC and perivascular cells from
luminal endothelial cells. In our studies we employed
cross-reactive anti-a-SMA which did not discriminate
mouse (host) from human (implant) cells. This antibody
stained brightly and in most cases it appeared to stain the
endothelial lumen of vessels (Figure 2 and Additional
file 1, Figures 2a and 2b) as has been reported for some
human and mouse vessels [38]. It also stained human
EOC and HUVEC grown in vitro (not shown), which
have also been reported to express a-SMA[39], so anti-
a-SMA is not specific for perivascular cells and is
expressed on luminal endothelial cells, at least in some
cases. In some areas of most sponge sections acellular
(non-nucleated) deposits of a-SMA were identified
by this antibody (Additional file 1, Figure 2a, row B
and Figure 2b, row C). This anti-a-SMA also stained
perivascular cells in some vessels (see Additional file 1,
Figure 2a, rows A and C) in that such cells appeared in
an adjacent layer peripheral to the lumen, and often with
their long axis vertical to the lumen. Similarly, apparent
perivascular layers peripheral to the lumen in mouse-
only vessels were also identified with anti-CD31 (Addi-
tional file 1, Figure 3a, row A), anti-endoglin (CD105)
(Additional file 1, Figure 4a row C) and anti-CD146
(Additional file 1, Figure 5a, row B). Thus, all the cross-
reactive antibodies, including anti-a-SMA, did not discri-
minate between endothelial or perivascular cells. This
also differs from the report by Melero-Martin et al. [32],
where a-SMA is claimed to be associated only with MSC
and not endothelial cells. The occurrence of vessels with
perivascular layers was confined to a minority of mouse-
only vessels, was never found where human cells incor-
porated into vessels, and had no discernible association
with any implanted cell type. We draw no conclusions
from this but note their presence and their prominent
vivid staining, especially by anti-a-SMA, but also by
other antibodies.
While HUVEC, expanded routinely in vitro through two
to three passages, showed normal growth and tubule for-
mation in Matrigel, they did not incorporate into vessels
when implanted in sponges. In contrast, freshly isolated
HUVEC, not yet passaged, incorporated into host vessels
(Table 3). According to Ingram et al., freshly isolated ves-
sel endothelial cells should contain EPC [36], but it
appears that they quickly lose the ability to incorporate
into vessels on expansion in vitro. EOC also eventually
lost the ability to incorporate after extensive passage
(Table 3). We have not characterized the kinetics of this
loss of incorporation ability either in EOC or HUVEC, but
it could reflect a change from progenitor to mature
endothelial cell. We have not identified anything within
growth characteristics, expression of a wide range of sur-
face markers, or patterns of expression of various genes,
that discriminates EOC from mature HUVEC other than
this ability to incorporate into vessels in the sponge model
of angiogenesis (Tura et al., manuscript submitted). This
should be examined further. We also note that while EOC
were cultured on type-1 collagen, HUVEC were cultured
on uncoated plastic, and the possible role of extracellular
matrix in maintaining immature status or promoting
maturation should be investigated. Cells for therapeutic
use should be capable of incorporation into vessels, so it is
important to retain this property during in vitro expansion
if EOC are to be used for vascular regenerative therapy.
The sponge model can examine this property.
Neither adherent monocytes, nor MNC cultured on
fibronectin, influenced sponge vascularization by incor-
poration or proangiogenic activity. Indeed, of all the cells
studied, adherent monocytes slightly, but not significantly,
inhibited vascularization (Table 2). However, isolated
human cells expressing endothelial markers were found in
the sponges in which monocyte-enriched cells were
implanted. The derivation of early CFU-EPC from mono-
cytes on fibronectin, and numerous other reports of
expression of endothelial markers by monocytes when cul-
tured on fibronectin [26,27,29], suggest that the cells
observed in the sponges are monocytes, or were derived
from them. The culture of MNC on either fibronectin or
collagen to produce putative EPC has caused some confu-
sion between true EOC and differentiated monocytes. Our
experience (unpublished) suggests that culture on fibro-
nectin produces monocyte-derived cells that can mimic
endothelial cells by phenotype, whereas, consistent with
other reports [28], true EPC are produced only on collagen
type-1. However, others have described production of
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functional EOC on fibronectin [40] or even on uncoated
plastic[41] under certain circumstances, so it may be that
the collagen effect is quantitative rather than mandatory.
However, since monocytes appear to require fibronectin
for endothelial-like differentiation and formation of early
CFU-EPC, the exclusive use of type-1 collagen for
endothelial outgrowth from MNC might avoid any confu-
sion between true EOC and differentiated monocytes.
Since monocytes did not apparently influence vessel
growth in this study, they may not be an important com-
ponent of cellular therapy for vascular regeneration, and
may be irrelevant when considering acquisition of cells for
that purpose. However, since there is a non-specific host
inflammatory response to the sponge and migration of
host inflammatory cells, including monocytes, into the
sponge, it may be that this masks any stimulatory effect
provided by the addition of human monocytes. If mono-
cytes or their derivatives have a masked proangiogenic
effect, it must be different from the proangiogenic effect of
HPC, which is evident. It has also been suggested that
monocytes may have an ability to infiltrate ischemic tissue
and provide pathways for vascularization by endothelial
cells [42,43], which may not have been tested in this
model.
While EOC have been proposed as an option for thera-
peutic vascular regeneration [44,41], to date all clinical
trials have employed HPC from patients’ autologous
bone marrow or G-CSF-mobilized peripheral blood.
Some recent studies show that bone marrow-derived
HPC-like cells do not contribute to angiogenesis by
incorporation into regenerating vascular endothelium
[45-47]. Our study shows that the prominent, and possi-
bly the only, angiogenic potential of HPC-like cells is
proangiogenic activity, not as sources of EPC. This
proangiogenic activity is not seen at low HPC frequency
in unfractionated MNC and is only found when HPC are
enriched through CD34+ cell selection, so is evidently
quantitatively related to CD34+ cell numbers. Neither
EOC nor HUVEC showed a proangiogenic effect despite
EOC and early HUVEC showing incorporation into ves-
sels, so their role seems passive, dependent only on avail-
ability. It is notable that the strongest, most significant
proangiogenic effect came from G-CSF-mobilized CD34+
cells, followed by cord blood CD34+ cells, and that sur-
prisingly bone marrow-derived CD34+ cells were not
proangiogenic in this model. While HPC may be charac-
terized by expression of CD34 or CD133, these markers
are not equivalent or homogeneously expressed by HPC,
and different subpopulations exist which are CD34
+CD133-, CD34+CD133+ and CD34-CD133+ [24]. The
observed proangiogenic capacity follows the proportions
that we have found in different HPC sources of CD34+
cells that co-express CD133, which are greatest in mobi-
lized blood HPC (around 80%), intermediate in cord
blood HPC (around 53%) and smallest in bone marrow
HPC (around 13%)[24]. It has been reported that CD133
+ HPC are proangiogenic, without incorporating into
neovessels [19,48]. Recently it has been shown that in
subpopulations of CD34+ HPC that differ in complex
phenotype only by CD133 expression, the CD133+ cells
show proangiogenic activity, while the CD133- cells do
not [49]. Thus, it may be that the proangiogenic effect is
mediated only by (some or all) CD133+ cells, but not by
CD133- cells. This might explain the differences we
found between the various sources of HPC, reflecting the
proportions of CD34+ cells that co-express CD133+. If so,
this could indicate that expression of CD133 may be bet-
ter than expression of CD34 for selection for proangio-
genic HPC. Further studies are needed to determine and
characterize subpopulations of HPC-expressing proan-
giogenic activity, and whether they can be expanded or
enhanced in vitro for therapeutic use.
This study suggests that any observed clinical benefit
reported in trials of HPC therapy for vascular regenera-
tion has predominantly been mediated by indirect
proangiogenic effects rather than through direct incor-
poration of any EPC contained within these HPC
sources. This may especially be the case in trials that
have employed CD133+ cells enriched from HPC
sources, since these would be depleted of CD34+CD133-
cells recognised as EPC. Since the main therapeutic tar-
gets remain myocardial and severe peripheral ischemia,
and the therapeutic options are confined to use of auto-
logous cells because of requirements for histocompat-
ibility, the current clinically available HPC sources are
either bone marrow or mobilized peripheral blood HPC.
Neither of these contain EPC detectable through
endothelial outgrowth, and their CD34+ cells appear at
opposite ends of the spectrum in their proangiogenic
activity. Since neither source seems to provide EPC, it
seems from this study that since mobilized blood HPC
are the more potent proangiogenic cells, they could be
preferred over bone marrow for autologous therapeutic
vascular regeneration. With regard to provision of EPC
for therapeutic use, the best available source for autolo-
gous EOC would seem to be normal peripheral blood,
not bone marrow or mobilized peripheral blood HPC. It
should be possible to produce autologous EOC for ther-
apeutic use [41,50], and clinical trials are needed to eval-
uate the effect of EPC distinct from or in synergy with
the proangiogenic effects of HPC therapies. Since the
endothelial progenitor cell has been the primary focus
of most studies, new studies are now required to clarify
the identity of the proangiogenic effector cell and the
mechanisms by which it delivers its effect, which may
have been the only clinical effect observed until now. It
may be that since the proangiogenic cell does not inte-
grate into tissue, it may have less stringent
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histocompatibility requirements for clinical use, or the
proangiogenic effect could be delivered by cell-free sys-
tems. The precursor and proangiogenic activities appear
to be the main components required to improve the
design of cellular therapy for vascular regeneration. The
role of other cells such as MSC or monocytes may be
relatively marginal, but might provide some added bene-
fit once the main progenitor and proangiogenic compo-
nents are optimized.
Conclusions
Clinical vascular regeneration trials employing autologous
hematopoietic progenitor cells have been based on the
assumption that endothelial progenitors coexist with
hematopoietic progenitors, and may share a common pre-
cursor. It is further assumed that endothelial progenitors
home to sites of vascular regeneration and contribute to
vessel formation by incorporating into new vessels. These
assumptions are complicated by the fact that distinct
endothelial and hematopoietic progenitors share many
phenotypic markers, and that hematopoietic progenitors
can promote angiogenesis. This study of the effects of dif-
ferent human cells on spontaneous vascularization in a
mouse model supports recent studies showing that the
contribution of autologous HPC to vascular regeneration
comes from indirect proangiogenic effects. EPC that give
rise to EOC, which incorporate into newly formed vascula-
ture, are extremely rare in HPC sources. EOC could be
isolated only from normal peripheral blood or umbilical
cord blood, but could not be isolated from bone marrow
or G-CSF-mobilized peripheral blood, which have until
now been the sources of autologous HPC used for thera-
peutic vascular regeneration. Further, mobilized peripheral
blood CD34+ cells (HPC) were the most potent proangio-
genic cells, and bone marrow CD34+ cells were surpris-
ingly without proangiogenic activity at the cell doses
tested. This may indicate that G-CSF-mobilized peripheral
blood may be preferred to bone marrow for cell therapy
for promotion of vascular repair. Further studies are
needed to determine whether true EPC have a role in ther-
apeutic vascular repair, and to elucidate the nature of the
differences in proangiogenic potency between different
HPC sources of CD34+ cells.
Additional material
Additional file 1: Extended set of fluorescent
immunohistochemistry images of vessels stained with each
antibody pair. Figure S1. No primary antibodies: control. Figure S2a.
Primary antibodies: cross-reactive rabbit anti-a-smooth-muscle actin with
human-specific mouse anti-CD31. Examples of images of mouse-only
vessels without incorporated human cells. Figure S2b. Primary
antibodies: cross-reactive rabbit anti-a-smooth-muscle actin with human-
specific mouse anti-CD31. Examples of images of vessels with
incorporated human cells. Figure S3a Primary antibodies: cross-reactive
rabbit anti-CD31 with human-specific mouse anti-CD146. Examples of
images of mouse-only vessels without incorporated human cells. Figure
S3b. Primary antibodies: cross-reactive rabbit anti-CD31 with human-
specific mouse anti-CD146. Examples of images of vessels with
incorporated human cells. Figure S4a Primary antibodies: cross-reactive
rabbit anti-CD105 (endoglin) with human-specific mouse anti-CD106
(VCAM-1). Examples of images of vessels showing only anti-CD105
binding. No vessels were found showing anti-CD106 binding, so vessels
incorporating human cells can not be distinguished from host-only
(mouse) vessels. Figure S4b Primary antibodies: cross-reactive rabbit anti-
CD105 (endoglin) with human-specific mouse anti-CD106 (VCAM-1).
Examples of images of human cells (bound by human-specific anti-
CD106) which remain free in sponges and are not associated with
vessels or other structures. FigureS5a Primary antibodies: cross-reactive
rabbit anti-CD146 with human-specific mouse anti-von Willebrand factor.
Examples of images of mouse-only vessels without incorporated human
cells. Figure S5b Primary antibodies: cross-reactive rabbit anti-CD31 with
human-specific.
Abbreviations
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